These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24364139)

  • 1. [A molecular basis of the plague vaccine development].
    Dentovskaia SV; Kopylov PKh; Ivanov SA; Ageev SA; Anisimov AP
    Mol Gen Mikrobiol Virusol; 2013; (3):3-12. PubMed ID: 24364139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Live-attenuated Yersinia pestis vaccines.
    Wang X; Zhang X; Zhou D; Yang R
    Expert Rev Vaccines; 2013 Jun; 12(6):677-86. PubMed ID: 23750796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The natural history and incidence of Yersinia pestis and prospects for vaccination.
    Williamson ED; Oyston PCF
    J Med Microbiol; 2012 Jul; 61(Pt 7):911-918. PubMed ID: 22442294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current challenges in the development of vaccines for pneumonic plague.
    Smiley ST
    Expert Rev Vaccines; 2008 Mar; 7(2):209-21. PubMed ID: 18324890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deadly plague versus mild-mannered TLR4.
    Dziarski R
    Nat Immunol; 2006 Oct; 7(10):1017-9. PubMed ID: 16985495
    [No Abstract]   [Full Text] [Related]  

  • 6. Expression of Yersinia pestis V antigen in attenuated salmonella typhimurium: development of a novel vaccine for plague.
    Leary SE; Eley SM; Williamson ED; Titball RW
    Contrib Microbiol Immunol; 1995; 13():216-7. PubMed ID: 8833838
    [No Abstract]   [Full Text] [Related]  

  • 7. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
    Eyles JE; Butcher WA; Titball RW; Hill J
    Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs.
    Feodorova VA; Pan'kina LN; Savostina EP; Sayapina LV; Motin VL; Dentovskaya SV; Shaikhutdinova RZ; Ivanov SA; Lindner B; Kondakova AN; Bystrova OV; Kocharova NA; Senchenkova SN; Holst O; Pier GB; Knirel YA; Anisimov AP
    Vaccine; 2007 Nov; 25(44):7620-8. PubMed ID: 17913308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for new plague vaccines.
    Feodorova VA; Corbel MJ
    Expert Rev Vaccines; 2009 Dec; 8(12):1721-38. PubMed ID: 19943765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological characterisation of sub-units of the Yersinia type III secretion apparatus.
    Hill J; Underwood CD; Sundberg L; Aström H; Leary SE; Forsberg A; Titball RW
    Adv Exp Med Biol; 2003; 529():415-7. PubMed ID: 12756800
    [No Abstract]   [Full Text] [Related]  

  • 11. Construction of defined F1 negative mutants of virulent Yersinia pestis.
    Worsham PL; Stein MP; Welkos SL
    Contrib Microbiol Immunol; 1995; 13():325-8. PubMed ID: 8833864
    [No Abstract]   [Full Text] [Related]  

  • 12. [The use of inbred mice for studying the protective properties of Yersinia pestis antigens].
    Zadumina SIu; Nazarova LS; Isupov IV; Pavlova LP; Tikhomirova EI
    Zh Mikrobiol Epidemiol Immunobiol; 1995; (6):69-70. PubMed ID: 8553769
    [No Abstract]   [Full Text] [Related]  

  • 13. [A method of assessing immunogenicity of preparations for plague prevention].
    Vasil'eva GI; Doroshenko EP; Kiseleva AK; Bespalova IA
    Klin Lab Diagn; 1999 Mar; (3):37-9. PubMed ID: 10234932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Infectious-toxic model of plague in mice].
    Ryzhko IV; Mishan'kin BN; Tsuraeva RI; Shcherbaniuk AI; Anisimov BI
    Zh Mikrobiol Epidemiol Immunobiol; 2009; (3):46-50. PubMed ID: 19621819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mice naturally resistant to Yersinia pestis Delta pgm strains commonly used in pathogenicity studies.
    Congleton YH; Wulff CR; Kerschen EJ; Straley SC
    Infect Immun; 2006 Nov; 74(11):6501-4. PubMed ID: 16954401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
    Gupta G; Khan AA; Rao DN
    Scand J Immunol; 2010 Mar; 71(3):186-98. PubMed ID: 20415784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newly described cell type may prove valuable in development of plague vaccines against biowarfare.
    Expert Rev Vaccines; 2011 Mar; 10(3):259. PubMed ID: 21434794
    [No Abstract]   [Full Text] [Related]  

  • 18. Further development of raccoon poxvirus-vectored vaccines against plague (Yersinia pestis).
    Rocke TE; Iams KP; Dawe S; Smith SR; Williamson JL; Heisey DM; Osorio JE
    Vaccine; 2009 Dec; 28(2):338-44. PubMed ID: 19879228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A plant-produced plague vaccine candidate confers protection to monkeys.
    Mett V; Lyons J; Musiychuk K; Chichester JA; Brasil T; Couch R; Sherwood R; Palmer GA; Streatfield SJ; Yusibov V
    Vaccine; 2007 Apr; 25(16):3014-7. PubMed ID: 17287055
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Sebbane F; Uversky VN; Anisimov AP
    Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33202679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.